TBC 3342

Drug Profile

TBC 3342

Alternative Names: TBC3342

Latest Information Update: 04 Feb 2008

Price : $50

At a glance

  • Originator Encysive Pharmaceuticals
  • Class
  • Mechanism of Action Integrin alpha4beta1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 05 Aug 2003 No development reported - Preclinical for Multiple sclerosis in USA (unspecified route)
  • 05 Aug 2003 No development reported - Preclinical for Asthma in USA (unspecified route)
  • 21 May 2003 Texas Biotechnology Corporation is now called Encysive Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top